(125 days)
No
The document describes software updates and hardware changes to an existing MR system. There is no mention of AI, ML, or related concepts in the intended use, device description, or performance studies.
No.
The device is indicated for use as a magnetic resonance diagnostic device to produce images and/or spectra that assist in diagnosis, not for therapeutic purposes.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "indicated for use as a magnetic resonance diagnostic device (MRDD)" and that images and derived physical parameters "when interpreted by a trained physician, yield information that may assist in diagnosis."
No
The device description explicitly states that the software is for the MAGNETOM Spectra system and lists several hardware updates that are part of the device, including new coils and modifications to other hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is a "magnetic resonance diagnostic device (MRDD)" that produces images and/or spectra of the internal structure and/or function of the head, body, or extremities. This is a description of an imaging device used for in-vivo diagnosis, not an in-vitro diagnostic device which analyzes samples outside the body.
- Device Description: The description details hardware and software components related to an MRI system, including coils, a reconstruction system, and a workplace for image acquisition and processing. These are all characteristic of an imaging device.
- Input Imaging Modality: The input modality is "Magnetic Resonance," which is an imaging technique.
- Anatomical Site: The device is used to image the "head, body, or extremities," indicating it is used on a living patient.
IVD devices are used to examine specimens (like blood, urine, tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. This device operates by imaging the body directly.
N/A
Intended Use / Indications for Use
The MAGNETOM Spectra is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
Product codes (comma separated list FDA assigned to the subject device)
LNH, LNI, MOS
Device Description
The subject device, Software syngo MR E11M for the MAGNETOM Spectra, is the latest software version for the Siemens MR MAGNETOM Spectra. It is modified based on the software version syngo MR E11A, which was cleared with K141977 on November 19, 2014. The software functionality and applications are based on syngo MR E11A except in technical instances where adaptations were needed to support the system specific hardware and optimize the sequence/protocols. System tests validating the aforementioned adapations are provided in Appendix 9.
Listed below are the hardware updates to the MAGNETOM Spectra systems with software syngo MR E11M:
- two new coils
- a modified MARS(Measurement and Reconstruction System) .
- an updated MRAWP/MRWP(Syngo Acquisition Workplace/ Syngo . Workplace) based on the new host platform
- minor hardware changes to the transmit unit
The MAGNETOM Spectra with software version syngo MR E11M will be offered ex-factory (new production) as well as in-field upgrades for the currently installed MAGNETOM Spectra systems.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance (MR)
Anatomical Site
head, body, or extremities
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained physician, healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical Tests:
- The coils were tested for SNR, image uniformity, and heating.
- All other software features were verified and validated.
The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
Clinical Tests:
No clinical tests were conducted to support the subject device and the substantial equivalence argument, however clinical images were provided to support the new coils of the subject device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around it. Inside the circle is a stylized emblem featuring a symbol that resembles a bird or a stylized human figure, composed of three overlapping profiles.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 31, 2016
Siemens Medical Solutions USA, Inc. % Cordell Fields, Esq. Regulatory Affairs Specialist 65 Valley Stream Parkway MALVERN PA 19355
Re: K153447
Trade/Device Name: MAGNETOM Spectra Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: II Product Code: LNH Dated: March 17, 2016 Received: March 18, 2016
Dear Mr. Fields:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Robert Oole
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows the word "SIEMENS" in a bold, sans-serif font. The color of the text is a bright teal. The letters are evenly spaced and the word is horizontally oriented.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
10(k) Number (if known
Image /page/2/Picture/6 description: The image shows the text 'K15344' at the top. Below that, the text 'Device Name' is present, followed by 'MAGNETOM Spectra'. The text appears to be a label or identifier for a device named MAGNETOM Spectra.
Indications for Use (Describe)
The MAGNETOM Spectra is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) | |
|---|---|---|
| -- | ---------------------------------------------- | --------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
3
Section 5 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92.
I. General Information Establishment Siemens Medical Solutions USA. Inc. 65 Vallev Stream Parkwav Mail Code 65-1A Malvern, PA 19355, USA Registration Number 2240869 Date Prepared November 24, 2015 Manufacturer SIEMENS SHENZHEN MAGNETIC RESONANCE LTD. Siemens MRI Center Hi-Tech Industrial park (middle) Gaoxin C. Ave., 2nd Shenzhen 518057. P.R. CHINA Registration Number: 3004754211 Siemens AG Henkestrasse 127 D-91052 Erlangen, Germany Registration Number: 3002808157 Contact Person Mr. Cordell L. Fields, Esq. Regulatory Affairs Specialist Siemens Healthcare Siemens Medical Solutions USA, Inc. Customer Solutions Group 65 Valley Stream Parkway Mail Code 65-1A Malvern, PA 19355, USA Phone: (610) 448-6469 Fax: (610) 448-1787
Device Name Software syngo MR E11M for the MAGNETOM Spectra
4
Image /page/4/Picture/0 description: The image shows the word "SIEMENS" in all capital letters. The font is a sans-serif typeface, and the letters are a bright teal color. The background is plain white, which makes the text stand out.
Trade Names:
Classification Name: Classification Panel: CFR Code: Classification: Product Code:
MAGNETOM Spectra
Magnetic Resonance Diagnostic Device (MRDD) Radiology 21 CFR § 892.1000 Class II Primary: LNH, Secondary: LNI, MOS
5
II. Safety and Effectiveness Information Supporting Substantial Equivalence
Indicatons for Use
The MAGNETOM Spectra is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
Device Description
The subject device, Software syngo MR E11M for the MAGNETOM Spectra, is the latest software version for the Siemens MR MAGNETOM Spectra. It is modified based on the software version syngo MR E11A, which was cleared with K141977 on November 19, 2014. The software functionality and applications are based on syngo MR E11A except in technical instances where adaptations were needed to support the system specific hardware and optimize the sequence/protocols. System tests validating the aforementioned adapations are provided in Appendix 9.
Listed below are the hardware updates to the MAGNETOM Spectra systems with software syngo MR E11M:
- · two new coils
- a modified MARS(Measurement and Reconstruction System) .
- an updated MRAWP/MRWP(Syngo Acquisition Workplace/ Syngo . Workplace) based on the new host platform
- . minor hardware changes to the transmit unit
The MAGNETOM Spectra with software version syngo MR E11M will be offered ex-factory (new production) as well as in-field upgrades for the currently installed MAGNETOM Spectra systems.
Technological Characteristics
MAGNETOM Spectra with syngo MR E11M and the predicate device, MAGNETOM Spectra with syngo MR D12, are substantially equivalent with regard to acquiring MR images steps/features.
6
SIEMENS
MAGNETOM Spectra with syngo MR E11M and the predicate device are substantially equivalent with regard to operational environment, programming lanquage, operating system and performance.
MAGNETOM Spectra with syngo MR E11M and MAGNETOM Spectra with software syngo MR D12 both conform to the standard for software medical devices (IEC 62304:2006) and IEC as well as NEMA standards.
Nonclinical Tests
The following performance testing was conducted on the subject device:
- The coils were tested for SNR, image uniformity, and heating. .
- All other software features were verified and validated. .
The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
Clinical Tests
No clinical tests were conducted to support the subject device and the substantial equivalence argument, however clinical images were provided to support the new coils of the subject device.
Safety and Effectiveness
The device labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the device.
Risk management is ensured via a risk analysis in compliance with ISO 14971:2007 to identify and provide mitigation to potential hazards in a risk analysis beginning early in the design phase and continuing throughout the development of the product. These risks are controlled via measures realized in software development, SW testing and product labeling. To minimize risks, Siemens adheres to recognized and established industry practices and standards, such as the IEC 60601-1 series, to minimize electrical and mechanical risk. Furthermore, the operators are healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.
The MAGNETOM Spectra with software syngo MR E11M conform to the applicable FDA recognized and international IEC, ISO and NEMA standards with regards to performance and safety as recommended by the respective MR FDA Guidance Document. The standards conformed to are the following:
| 19-4 | General | C1:2009/(R)2012 and
A2:2010/(R)2012
(Consolidated Text) Medical
electrical equipment – Part
1: General requirements for
basic safety and essential
performance (IEC 60601- | ES60601-
1:2005/(R)20
12 and
A1:2012 | AAMI ANSI |
| ------ | --------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------- | ----------- |
|---|
7
SIEMENS
| 19-1 | General | 1:2005, MOD)
Medical electrical
equipment - Part 1-2:
General requirements for
basic safety and essential
performance - Collateral
standard: Electromagnetic
compatibility -
Requirements and tests | 60601-1-2
Edition
3:2007-03 | IEC |
|--------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----|
| 12-207 | Radiology | Medical electrical
equipment - Part 2-33:
Particular requirements for
the basic safety and
essential performance of
magnetic resonance
equipment for medical
diagnostic | 60601-2-33
Edition 3.0
2010-03 | IEC |
| 5-40 | General | Medical devices -
Application of risk
management to medical
devices | 14971
Second
edition 2007-
03-01 | ISO |
| 5-89 | General | Medical electrical
equipment -- Part 1-6:
General requirements for
basic safety and essential
performance -- Collateral
Standard: Usability | 60601-1-6
Edition 3.1
2013-10 | IEC |
| 13-8 | Software | Medical device software -
Software life cycle
processes | 62304 First
edition 2006-
05 | IEC |
Substantial Equivalence
While t new and modified software and hardware featuresgive the subject device greater capabilities than the primary predicate device, MAGNETOM Spectra with software syngo MR D12, these additional capabilities are currently cleared features of secondary predicate device, MAGNETOM Skyra with software syngo MR E11A. (K141977; November 19, 2014) We believe the subject device to be substantially equivalent to the predicate devices.
| Predicate Device Name | Clearance | Product
code | Manufacturer |
|--------------------------------------------------------------|-------------------------------------|-----------------|---------------------------------------------------|
| MAGNETOM Spectra with
syngo MR D12
(Primary Predicate) | K121160
cleared July 16,
2012 | LNH,
LNI,MOS | Siemens
Shenzhen
Magnetic
Resonance Ltd. |
8
| Predicate Device Name | Clearance | Product
code | Manufacturer |
|-----------------------------------------------------------------------|-----------|-----------------|-------------------------------|
| Siemens MAGNETOM Skyra
with syngo MR E11A
(Secondary Predicate) | K141977 | LNH | Siemens
Healthcare
GmbH |
Conclusion as to Substantial Equivalence
There are no changes to the Indications for Use for the subject device, compared to that of the predicate device MAGNETOM Spectra with software syngo MR D12.
While the updated software provides the user with additional capabilities compared to the primary predicate device,MAGNETOM Spectra with software version syngo MR D12, these software features have been cleared with secondary predicate device MAGNETOM Skyra with software syngo MR E11A (K141977; November 19, 2014). While these additions for the subject device offer additional functionality to the end user, all of these features, as mentioned above, have been previously cleared and can be compared to existing features in the subject device and reference device. The different technological characterisitics of the new software do not raise new questions of safety and effectiveness.
Therefore, Siemens believes that the subject device, software version syngo MR E11M for MAGNETOM Spectra, is substantially equivalent to the predicate devicesmentioned above.